Airway remodeling, a characteristic feature of asthma, begins in early life. Recurrent human rhinovirus (HRV) infections are a potential inciting stimulus for remodeling. One component of airway remodeling is an increase in airway smooth muscle cell (ASMC) mass with a greater proximity of the ASMCs to the airway epithelium. We asked whether human bronchial epithelial cells infected with HRV produced mediators that are chemotactic for ASMCs. ASMC migration was investigated using the modified Boyden Chamber and the xCELLigence Real-Time Cell Analyzer (ACEA Biosciences Inc., San Diego, CA). Multiplex bead analysis was used to measure HRV-induced epithelial chemokine release. The chemotactic effects of CCL5, CXCL8, and CXCL10 were also examined. Supernatants from HRV-infected epithelial cells caused ASMC chemotaxis. Pretreatment of ASMCs with pertussis toxin abrogated chemotaxis, as did treatment with formoterol, forskolin, or 8-bromo-cAMP. CCL5, CXCL8, and CXCL10 were the most up-regulated chemokines produced by HRV-infected airway epithelial cells. When recombinant CCL5, CXCL8, and CXCL10 were used at levels found in epithelial supernatants, they induced ASMC chemotaxis similar to that seen with epithelial cell supernatants. When examined individually, CCL5 was the most effective chemokine in causing ASMC migration, and treatment of supernatant from HRV-infected epithelial cells with anti-CCL5 antibodies significantly attenuated ASMC migration. These findings suggest that HRV-induced CCL5 can induce ASMC chemotaxis and thus may contribute to the pathogenesis of airway remodeling in patients with asthma.
Clinical Relevance
The current research supports the concept that human rhinovirus infections may be a trigger for airway remodeling in childhood asthma. By identifying underlying mechanisms, it may be possible to limit airway remodeling in asthma.
The airways of patients with asthma typically display a number of structural changes, including goblet cell metaplasia and excessive mucus production, thickening of the lamina reticularis, angiogenesis, and increased smooth muscle mass, with a reduced distance between muscle cells and the airway epithelium as asthma severity increases (1, 2) . These changes, collectively termed "airway remodeling," lead to a thickening of the airway wall. This has been suggested to contribute to airways hyperresponsiveness, in part by induction of increased airway narrowing for a given degree of smooth muscle shortening (3, 4) .
In most patients, asthma initially manifests in childhood (5) . It is therefore noteworthy that, although it was traditionally believed that airway remodeling occurred after years of chronic inflammation, a number of bronchial biopsy studies have now established that several major components of airway remodeling, including increased smooth muscle mass and thickening of the lamina reticularis, are already present in preschool children, often before the clinical diagnosis of asthma has been made (6) (7) (8) . Interestingly, signs of airway remodeling are not detected in infants with wheezing illnesses (9) , implying that exposure to some inciting stimuli in early childhood induces remodeling.
It is now well established that children who experience human rhinovirus (HRV)-induced wheezing illnesses in early life are at increased risk of subsequently developing asthma (10, 11) , particularly if they are also sensitized to inhaled allergens (12) . Preschool-age children have been shown to experience approximately six HRV infections each year (13) , and serial HRV infections can cause recurrent wheezing episodes (14) . Given the concomitant time frame of recurrent HRVinduced wheezing episodes and the development of airway remodeling, it is feasible that HRV infections could contribute to the initiation and progression of airway remodeling in asthma. In the current studies, we tested the hypothesis that HRV infection of airway epithelial cells induces release of chemotactic agents that could cause directional migration of airway smooth muscle cells (ASMCs) toward the epithelium to contribute to the process of remodeling.
Materials and Methods
Details regarding all methods are provided in the online supplement.
Cell Cultures
Primary human bronchial epithelial (HBE) cells were obtained via protease digestion of nontransplanted normal human bronchi, as described previously (15) , and grown in bronchial epithelial growth medium. For these studies, cells were derived from six lung donors (five male; age range, 13-63 yr). All six donors died from nonrespiratory causes, and none of them had any underlying lung disease. Human ASMCs were obtained by microdissection and protease digestion and cultured in Dulbecco's modified Eagle's medium containing 10% FBS and antibiotics, as described previously (16) . A total of 10 individual ASMC donors was used (eight male; age range, 13-63 yr). Protocols for obtaining cells were approved by the University of Calgary (Calgary, AB, Canada) Conjoint Health Ethics Board.
HRV Infection
HRV type 16 (HRV-16) was propagated in WI-38 cells and purified as described previously (17) . Viral titers were determined as described previously (17) . HBE cells were exposed to control medium or to 10 5.5 50% tissue culture infective dose U/ml (multiplicity of infection, z1.0) of HRV-16 for 24 hours at 34 8 C with 5% CO 2 . Epithelial cell supernatants from six individual donors were pooled for each experimental condition to generate stocks of conditioned medium (CM) and HRV-CM for migration experiments.
Migration Assay
ASMC migration was performed in both an AP48 modified Boyden chamber (NeuroProbe, Cabin John, MD) and the xCELLigence Real-Time Cell Analyzer (RTCA) system (ACEA Biosciences Inc., San Diego, CA). ASMCs were added to top wells of the AP48 chamber (40,000 cells/well) or the RTCA system (80,000 cells/well), whereas chemoattractants were added to the bottom chambers. Plateletderived growth factor (PDGF)-AB was used as a positive control stimulus for ASMC migration. Plates were incubated (4 h) at 37 8 C and 5% CO 2 . Impedance data for the RTCA system were normalized at the earliest time point to control for differences in well loading and cell settling. Migration experiments used ASMCs from the indicated number of individual tissue donors in each experiment (i.e., n = number of ASMC donors).
64-Chemokine Multiplex Assay
Pooled CM or HRV-CM was used in a 64-chemokine multiplex protein assay performed by Eve Technologies (Calgary, AB, Canada).
Flow Cytometry Analysis
ASMCs were suspended using a nonenzymatic cell dissociation buffer. Fluorescently labeled antibody(s) was then added and the cells were allowed to incubate in the dark at 4 8 C for 2 hours with rocking. Cells were fixed and stored at 4 8 C until analyzed by flow cytometry.
ELISA Assay for CXCL8
CXCL8 was assayed as previously described (18) .
Neutralizing Antibody Treatment of CM
Neutralizing monoclonal antibody to CXCL5, or appropriate isotype control, was added to HRV-CM and incubated at room temperature (2 h) before use as chemoattractants for ASMCs.
Cell Viability
Cell viability after experimental interventions was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.
Statistical Analysis
Data are presented as means (6SEM). Statistical analysis was performed by using ANOVA and the Newman Keuls multiple comparison post hoc test. P values of less than 0.05 were regarded as statistically significant. Statistical analysis was performed with GraphPad Prism 6 software (GraphPad Software, Inc., La Jolla, CA).
Results

ASMCs Migrate to CM from HRVInfected HBE Cells
Because the xCELLigence system provides real-time data, we used this apparatus to establish that ASMC migration started to plateau by 4 hours (see Figure E1 in the online supplement). Therefore, we used 4 hours as the outcome time point for all subsequent experiments.
Conditioned medium from HBE cells treated with medium control (CM) or HRV-16 (HRV-CM) for 24 hours were used as chemoattractants in both the Boyden chamber and the xCELLigence system. CM was able to drive a migratory response that was higher than the medium alone; however, the HRV-CM condition was able to drive significantly higher migration in both the Boyden chamber ( Figure 1A ) and the xCELLigence system ( Figure 1B) . HRV virion alone, at levels used to stimulate HBE cells, did not induce any migration of ASMCs ( Figure 1B ). We next examined whether ASMC migration was directional or random by abolishing the chemotactic gradient in the xCELLigence system by adding the chemoattractant to both the top and bottom wells ( Figure 1C ). Although CM and HRV-CM were able to drive ASMC migration normally, migration to both stimuli was significantly attenuated (P , 0.001) when there was no gradient present. Given the concordance in data from the modified Boyden chamber and the xCELLigence system, we used the xCELLigence system for all subsequent migration experiments.
Migration to HRV-CM Is Mediated by Molecules less than 30 kD and Chemoattractant Production Depends upon Viral Replication
To gain insight into the molecule(s) responsible for ASMC migration to HRV-CM, centrifugal filtration devices were used to remove all materials greater than 30 kD (including HRV virions) from the HBE cell supernatants. We validated that filtration did not retain low-molecular weight molecules by demonstrating minimal loss of CXCL8 levels in the filtrate ( Figure E2 ). Filtration did not alter the ability of HRV-CM to drive ASMC migration, but significantly attenuated the ability of CM alone to drive ASMC migration ( Figure 2A ). To study the time course of chemoattractant generation from HBE cells, we collected CM at 3, 9, 15, and 24 hours after HRV treatment. The chemotactic ability of HBE-CM for ASMCs increased with time after HRV infection ( Figure 2B ). To determine if this increase was dependent upon the replication of HRV, cells were exposed to either intact HRV, capable of replication, or to ultraviolet light-treated, replicationdeficient HRV. Medium from cells exposed to replication-competent virus generated a chemotactic response as shown, whereas medium from cells exposed to replicationdeficient HRV did not induce significant ASMC chemotaxis ( Figure 2C ), confirming that viral replication within HBE cells is necessary to promote chemoattractant release.
Exposure to Pertussis Toxin Inhibits ASMC Migration to HRV-CM
A number of low-molecular weight chemoattractants, including chemokines, exert their effects via G protein-coupled receptors (GPCRs), which are often linked to the G protein, Gai (19) . We therefore studied whether the chemoattractant(s) contained in HRV-CM act through a Gaicoupled GPCR by exposing ASMCs to pertussis toxin (PTX), which ADPribosylates and inactivates Gai, before performing migration assays. There was no deleterious effect of PTX on ASMC viability (data not shown). As anticipated, PTX did not attenuate migration to PDGF-AB, which functions via a receptor tyrosine kinase. In contrast, PTX significantly reduced ASMC migration to HRV-CM ( Figure 3 ).
ASMC Migration Is Sensitive to Intracellular cAMP
Given that Gai-coupled GPCRs can lower intracellular cAMP levels, we next examined the effects of elevating intracellular cAMP levels on ASMC migration. Activation of its Ga s -coupled GPCR by the b 2 -adrenergic agonist, formoterol, completely abolished migration to both CM and HRV-CM ( Figure 4A) . Similarly, direct activation of adenylyl cyclase in ASMCs using the forskolin analog, 6-(3-dimethylaminopropionyl) forskolin hydrochloride (NKH-477), or pretreatment with the cell-permeable cAMP analog, 8-bromoadenosine 39, 59-cyclic monophosphate, 15 minutes before use in the migration assay, also both abrogated the migratory capacity of the ASMCs (Figures 4B and 4C ). Given that migration to HRV-CM and the receptor tyrosine kinase-linked positive control, PDGF-AB, were both inhibited by agents that elevate intracellular cAMP, it is suggested that this is a broadranging regulatory pathway, and not simply a competitor to Gai-coupled GPCR-mediated reduction in intracellular cAMP.
Identification of Chemokines that Facilitate HRV-Induced ASMC Migration
To identify potential chemoattractants that may contribute to ASMC migration in response to HRV-CM, we performed a multiplex assay for 64 analytes (Luminex, Toronto, ON, Canada) on media obtained from a pool of six HBE cell donors exposed either to medium alone or to HRV. The four most highly up-regulated chemokines are shown in Figure 5 .
Flow Cytometry Data Indicate the Presence of Several Chemokine Receptors
Flow cytometry was performed to examine the expression of potential cell surface receptors for the chemokines identified previously here at the protein level. These experiments used ASMCs obtained from five donors. A representative series of histograms showing surface expression of CXCR1, CXCR2, CXCR3, CCR1, CCR3, and CCR5 on ASMCs from a single individual is shown ( Figure 6A ). Mean percentage of cells expressing each receptor using cells from all five donors is shown in Figure 6B . To determine the potential of CCL5, CXCL8, and CXCL10 to induce ASMC migration using concentrations similar to those found in HRV-CM, we initially used the recombinant chemokines in concentrations of 500 pg/ml, 5,000 pg/ml and 10,000 pg/ml, alone and in combination. The combination of the three chemokines induced ASMC migration that was significantly greater that that seem with CM and that was comparable to that observed for HRV-CM ( Figure 7A ). When examined individually, CXCL10 caused no significant migration, despite the high expression of CXCR3 on ASMCs. Moreover, CXCL8 alone induced only a modest chemotactic response, presumably mediated via interactions with CXCR1. By contrast, CCL5 alone induced migration similar to that seen with HRV-CM, suggesting that CCL5 is the major chemoattractant for ASMCs in HRV-CM. To further evaluate the role CCL5 in the ASMC migratory response, we incubated HRV-CM with a neutralizing antibody to CCL5 or with an isotype control. Although the isotype control did not alter ASMC migration, the antibody to CCL5 significantly abrogated ASMC migration to HRV-CM ( Figure 7B ).
Discussion
Preschool children who experience recurrent HRV-induced wheezing illnesses are not only at increased risk of subsequently developing asthma (10, 11) , but already show signs of airway remodeling, including increased airway 
. HRV-induced induction of chemoattractants from HBE cells depends upon viral replication and chemoattractants of less than 30 kD. (A) HRV-CM and CM were passed over a 30-kD filter, and migration to the filtrates (white bars) was compared with that of unfiltered CM (gray bars) (n = 3). (B) HRV-CM was harvested at multiple time points after HRV infection (3, 9, 15, and 24 h) and used in chemotaxis assays (n = 4). (C) CM from ultraviolet light (UV)-inactivated HRV-16-treated epithelial cells (UV-HRV-CM) is ineffective as a chemoattractant for ASMCs (n = 3). Black bars in each panel
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smooth muscle mass (8) . The relative contribution of hyperplasia versus hypertrophy to the increased smooth muscle mass in asthma is still somewhat controversial (20, 21) , and may vary depending on the size of airways examined (22) . The observation that ASMCs are found closer to the epithelium in asthma implies that ASMC migration also occurs in asthma (2) . Indeed, a number of studies have indicated that ASMCs are capable of migrating to a variety of growth factors, including PDGF (23), as well as to selected chemokines (24) (25) (26) (27) . In this study, we show that human airway epithelial cells infected with HRV release chemotactic agents that can cause directed migration of ASMCs toward the epithelial layer. The production of these chemoattactants depends upon viral replication within HBE cells, as CM from HBE cells exposed to ultraviolet light-treated, replicationdeficient HRV did not induce significant ASMC migration. To gain insights into the nature of the chemoattractants in HRV-CM, we first demonstrated that chemotactic activity was retained in the filtrate after passage through a 30,000-Dalton filter, indicating that chemotactic agents were of relatively low molecular weight. The observation that treatment of ASMCs with PTX abrogated ASMC migration to HRV-CM indicated that chemoattractant agents in HRV-CM act via interactions with Gai-coupled GPCR(s). Although a number of mediators satisfy these characteristics, the prior evidence for a role of chemokines in inducing ASMC migration in other systems (24) (25) (26) (27) led us to perform multiplex analysis of chemokines in supernatants from epithelial cells exposed to medium or HRV. Induction of CCL5, CXCL8, and CXCL10 identified these chemokines as potential candidates to cause ASMC chemotaxis, and this paradigm was further supported by detection of low-level expression of receptors for each chemokine on ASMCs by flow cytometry. Subsequent functional studies revealed that, CXCL10 was ineffective as a chemotactic agent for ASMCs, despite the expression of the CXCR3 receptor on a significant percentage of ASMCs. Although this seems paradoxical, these observations are consistent with those reported by Saunders and colleagues (28) . Presumably, the inability of CXCL10 to function as a chemoattractant for ASMCs relates to a lack of signaling downstream of the receptor. This is quite distinct from our prior data showing that generation of this chemokine from HRV-infected HBE cells plays an important role in causing chemotaxis of fibroblasts (29) . We also found that CXCL8 caused only modest ASMC migration, and that CCL5 was the most effective chemoattractant for ASMCs. We confirmed that CCL5 was a major contributor to the chemotactic activity of HRV-CM for ASMCs by demonstrating that incubation of HRV-CM with a specific blocking antibody to CCL5 largely abolished ASMC chemotaxis. Taken together, our data are consistent with earlier reports that CCL5 derived from TNF-a-stimulated epithelial cells was chemotactic for ASMCs (30), and that CXCL8 can also stimulate ASMC migration (25, 30) .
We also demonstrated in this study that elevation of cAMP in ASMCs inhibits migration of these cells to a variety of stimuli, including HRV-CM and PDGF. This was the case whether cAMP was induced via activation of the b 2 -adrenergic receptor, via direct activation of adenylyl cyclase, or via use of a cell-permeable cAMP analog. These data are consistent with an earlier report of a modulatory role of cAMP in regulating ASMC migration (31) , but differ somewhat in that we found all mechanisms of cAMP elevation to be equally effective, whereas Goncharova and colleagues (31) found that inhibition of migration varied depending on the means of elevating cAMP. Our observation that a b 2 -adrenergic receptor agonist inhibits ASMC migration to a variety of stimuli raises the possibility that the use of b 2 -adrenergic receptor agonists may help to attenuate some aspects of remodeling in asthma. This would be consistent with a recent study showing that combination therapy with an inhaled corticosteroid and long-acting b 2 -adrenergic receptor agonist, but not an inhaled corticosteroid alone, inhibited antigen-induced alterations in airway smooth muscle and myofibroblast numbers in subjects with asthma (32) . Our study has several limitations. We used cells from adolescent and adult donors, and future studies will need to examine whether epithelial cells from young children will show similar chemotactic responses to HRV infection. In addition, both epithelial cells and ASMCs used in the current study were procured from healthy donors without asthma, in whom airway remodeling is unlikely to have been present. However, even in the airways of normal subjects infected with HRV, there is likely to be some effect and alteration in ASMC numbers, and this may be what is reflected in our current model in the setting of low chemokine receptor expression on ASMCs. We speculate that the chemotactic responses demonstrated in our present study would be exaggerated if cells from donors with asthma were used. Further studies will need to determine whether epithelial cells from subjects with asthma generate higher levels of chemokines after HRV infection, and, if so, whether ASMCs from these subjects with asthma show a greater chemotactic response to these chemotactic cytokines. In that context, given the modest level of expression of receptors for CCL5 on our normal cells, it is of interest that ASMCs from subjects with asthma show increased expression of the CCR3 chemokine receptor (24) , for which CCL5 is a known ligand. This would be expected to result in an increased number of ASMCs from subjects with asthma migrating to this chemokine.
In summary, we show that HRVinfected epithelial cells release chemoattractants that can stimulate directed migration of ASMCs. CCL5 is the dominant chemoattractant present in HRV-CM, although CXCL8 may also contribute. These data, together with earlier reports that HRVinfected epithelial cells show expression of genes related to airway remodeling (33) , and release a number of growth factors and matrix proteins linked to airway remodeling (34) (35) (36) , further support the concept that recurrent HRV infections may contribute to the initiation and progression of airway remodeling in asthma. Future studies will need to determine if the current observations are relevant to cells obtained from subjects with asthma (both children and adults), whereas clinical studies of either naturally acquired or experimental HRV infections will confirm whether these observations occur in vivo. n Figure 7 . CCL5 is the major chemoattractant for ASMCs in HRV-CM. (A) Migration of ASMCs was assessed using CXCL10 (10,000 pg/ml), CXCL8 (5,000 pg/ml), CCL5 (500 pg/ml), CM, or HRV-CM (n = 3). (B) ASMC migration was significantly inhibited after 1-hour pretreatment of HRV-CM with anti-CCL5 but not with isotype control (n = 3). Bars are defined by the 1 signs beneath each bar. *P , 0.05. Data are presented as means (6SEM).
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